Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedA banner about NIH terminology and transition updates was removed from the top of the page. The page continues to show a 403 Forbidden error.SummaryDifference1%

- Check16 days agoChange DetectedThe footer's displayed site revision changes from v3.7.2 to v3.8.0, while the study record remains unavailable behind a 403 error.SummaryDifference0.2%

- Check30 days agoChange DetectedA site-wide NIH announcement about using “Super Intelligence” in place of “Artificial Intelligence” appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The study record continues to display a 403 error.SummaryDifference1%

- Check37 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1. The study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now presents a 403 Forbidden error, preventing access to the study record content; previously visible details and navigation are no longer accessible.SummaryDifference18%

- Check64 days agoChange DetectedThe page's revision label was updated from v3.6.6 to v3.7.0. This indicates a behind-the-scenes maintenance release rather than a visible change to the content or layout.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.